CAPGEMINI HELPS BOEHRINGER INGELHEIM IN A WORLD OF DATA
Ruth Lütticken , Director of Life Sciences , Data Science & AI , Capgemini , explains how data management is helping Boehringer Ingelheim to transform lives
Pioneering family-owned Boehringer Ingelheim is making use of cutting-edge data management services provided by Capgemini in its work on breakthrough therapies .
Boehringer Ingelheim specialises in areas of unmet medical need in Human Pharma , Animal
Health , and Biopharmaceutical Contract
Manufacturing . As part of its Dataland program , Boehringer Ingelheim invests in data-related initiatives to strengthen its foothold in the digital world . Leveraging data has the potential to transform drug development and the patient experience . Several units within the organisation were already successfully working with data , but Boehringer Ingelheim wanted to scale its usage across the entire company .
This ambition required a strong technology foundation and modern infrastructure , as well as clear processes and responsibilities in the area of data governance .
“ It is a cloud-based ecosystem that we ’ re building for our data needs not just for today but the years to come in the future ,” explains Boehringer Ingelheim ’ s Head of Data Management , Bruno Rizzuti . “ This project is designed to create a trusted environment not only for our regular use cases but also for those that require more , let ’ s say , flexibility and the capabilities that the technology in the cloud can provide .”
“ There are many exciting use cases for data and human pharma ,” says Ruth Lütticken , Director of Life Sciences , Data Science & AI , Capgemini . “ I think since Covid 19 , everybody knows how important that step is in developing new tracks .
Here the change was for the global feasibility managers at the country level to select a certain trial site for a certain trial phase .
So many factors and data will have to be considered , and this gives them a predictive modelling solution which is using internal but also external data to allow them to have data-driven site identification , which means they can reduce the time for the trial .”
Learn more